We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $1.85M
1-Year Est. Return 176.16%
This Fund
S&P 500
This Quarter Est. Return
-5.66%
1 Year Est. Return
+176.16%
3 Year Est. Return
+511.75%
5 Year Est. Return
+854.95%
10 Year Est. Return
+8,566.11%
AUM
$108M
AUM Growth
-$175M
Cap. Flow
+$9.09M
Cap. Flow %
8.4%
Top 10 Hldgs %
92.43%
Holding
31
New
6
Increased
13
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.59M
2
MTEM
Molecular Templates, Inc.
MTEM
+$2.79M
3
SCYX icon
SCYNEXIS
SCYX
+$2.02M
4
KALA icon
KALA BIO
KALA
+$640K
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$489K

Top Sells

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$2.95M
2
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$763K
3
BBDC icon
Barings BDC
BBDC
+$302K
4
GARS
Garrison Capital Inc.
GARS
+$50.5K
5
MRKR icon
Marker Therapeutics
MRKR
+$26.9K

Sector Composition

Rank Sector Weight
1 Healthcare 60.64%
2 Miscellaneous 18.13%
3 Financials 17.98%
4 Real Estate 1.4%
5 Utilities 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$222K 0.21%
3,178
+1,786
+128% +$136K
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$202K 0.19%
5,045
+1,769
+54% +$50.3K
CACC icon
28
Credit Acceptance
CACC
$6.28B
$201K 0.19%
+459
New +$193K
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$190K 0.18%
2,797
+1,954
+232% +$177K
BBDC icon
30
Barings BDC
BBDC
$944M
– –
-26,286
Closed -$302K
ONCT
31
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-356
Closed -$763K
1
2

Similar funds

1IC
1922 Investment Company Houston, Texas $1.89M AUM 15.39% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
HGCK
HPC Germany & Co KG Potsdam, Germany $1.68M AUM 15.3% 1-Year Est. Return
CA
Cohalo Advisory Snoqualmie, Washington $1.65M AUM 11.44% 1-Year Est. Return
CAM
Creekmur Asset Management Morton, Illinois $2.07M AUM
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $1.56M AUM 25.68% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Caxton Corporation's Q3 2018 Portfolio in Review

As of Q3 2018, Caxton Corporation held 31 positions worth $108M, down 62% from $283M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Caxton Corporation deployed $9.09M of net new capital in Q3 2018, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was KALA BIO: 21 shares worth $506K.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 22% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Lite Strategy Inc, an estimated $2.95M trimmed.

  • Caxton Corporation's largest Q3 2018 buy was KALA BIO: 21 shares worth $506K.
  • Caxton Corporation added most to Strongbridge Biopharma plc. in Q3 2018, an estimated $4.59M increase.
  • Caxton Corporation's biggest Q3 2018 reduction was Lite Strategy Inc, cutting an estimated $2.95M.
  • Caxton Corporation fully exited Oncternal Therapeutics, Inc. Common Stock in Q3 2018, selling an estimated $763K.
  • Caxton Corporation's ten largest holdings make up 92% of its $108M portfolio in Q3 2018.
  • Caxton Corporation opened 6 new positions and closed 2 in Q3 2018.
  • Caxton Corporation's portfolio value fell 62% quarter-over-quarter to $108M.

Based on Caxton Corporation's 13F filing for Q3 2018, filed 14 Nov 2018.